Nkarta, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $190.5M
- Price
- $2.66
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.69%
- Volume
- 1.1M
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Quick stats
Shares outstanding71.6M
Computed float42.1M
Float / shares58.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001787400
Websitehttps://www.nkartatx.com
AI Summary
AI-generated1/10
minormixedearnings
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Nkarta reported a Q2 2026 net loss of $40.4 million, or $0.54 per share, widening from a loss of $23.0 million in the prior year period as R&D investments increased to $29.0 million.
The company is advancing its NKX019 autoimmune trials, Ntrust-1 and Ntrust-2, with ongoing enrollment at the 4 billion cell dose level and outpatient dosing now underway at community sites.
Nkarta ended the quarter with $243.2 million in cash, cash equivalents, and investments, which management expects will fund operations into 2029.
Red flags
- Net loss widened to $40.4M from $23.0M YoY
- Operating expenses increased 59% YoY to $43.1M